Literature DB >> 21765070

Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.

Whitney E Harrington1, Theonest K Mutabingwa, Edward Kabyemela, Michal Fried, Patrick E Duffy.   

Abstract

BACKGROUND: Millions of African women receive sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment during pregnancy (IPTp) to avoid poor outcomes that result from malaria. However, parasites resistant to SP are widespread in parts of Africa, and IPTp may perversely exacerbate placental infections that contain SP-resistant parasites.
METHODS: The study used a cross-sectional design. We determined IPTp use in a delivery cohort of 880 pregnant women in Muheza, Tanzania, by report and by plasma sulfa measurements, and we examined its effects on maternal and fetal delivery outcomes.
RESULTS: In the overall cohort, IPTp was not associated with decreased odds of placental malaria or with increased mean maternal hemoglobin or mean birth weight. Unexpectedly, IPTp was associated with decreased cord hemoglobin level and increased risk of fetal anemia, which may be related to in utero SP exposure.
CONCLUSIONS: IPTp does not improve overall pregnancy outcomes in Muheza, Tanzania, where SP-resistant parasites predominate and may increase the odds of fetal anemia. As parasite resistance increases in a community, the overall effect of IPTp may transition from net benefit to neutral or net harm.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21765070      PMCID: PMC3202321          DOI: 10.1093/cid/cir376

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Human maternofoetal distribution of pyrimethamine-sulphadoxine.

Authors:  T Trenque; C Marx; C Quereux; B Leroux; D Dupouy; P H Dorangeon; H Choisy; J M Pinon
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

2.  Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes.

Authors:  T Jelinek; A H Kilian; G Kabagambe; F von Sonnenburg
Journal:  Am J Trop Med Hyg       Date:  1999-09       Impact factor: 2.345

3.  Placental transfer and renal clearance of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole in a pregnant ewe.

Authors:  T B Vree; J J Reekers-Ketting; J F Nouws; T H Arts
Journal:  J Vet Pharmacol Ther       Date:  1983-03       Impact factor: 1.786

4.  Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.

Authors:  M E Parise; J G Ayisi; B L Nahlen; L J Schultz; J M Roberts; A Misore; R Muga; A J Oloo; R W Steketee
Journal:  Am J Trop Med Hyg       Date:  1998-11       Impact factor: 2.345

Review 5.  Fetal anaemia in malarious areas: its causes and significance.

Authors:  B Brabin
Journal:  Ann Trop Paediatr       Date:  1992

6.  Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic.

Authors:  Jeanne Rini Poespoprodjo; Wendy Fobia; Enny Kenangalem; Daniel A Lampah; Noah Warikar; Andrew Seal; Rose McGready; Paulus Sugiarto; Emiliana Tjitra; Nicholas M Anstey; Ric N Price
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

7.  HIV, malaria, and infant anemia as risk factors for postneonatal infant mortality among HIV-seropositive women in Kisumu, Kenya.

Authors:  Anna M van Eijk; John G Ayisi; Feiko O Ter Kuile; Laurence Slutsker; Ya Ping Shi; Venkatachalam Udhayakumar; Juliana A Otieno; Piet A Kager; Renu B Lal; Richard W Steketee; Bernard L Nahlen
Journal:  J Infect Dis       Date:  2007-05-16       Impact factor: 5.226

8.  Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta.

Authors:  M Fried; P E Duffy
Journal:  Science       Date:  1996-06-07       Impact factor: 47.728

9.  Plasmodium infection and its risk factors in eastern Uganda.

Authors:  Rachel L Pullan; Hasifa Bukirwa; Sarah G Staedke; Robert W Snow; Simon Brooker
Journal:  Malar J       Date:  2010-01-04       Impact factor: 2.979

10.  A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic.

Authors:  Clara Menéndez; Azucena Bardají; Betuel Sigauque; Cleofé Romagosa; Sergi Sanz; Elisa Serra-Casas; Eusebio Macete; Anna Berenguera; Catarina David; Carlota Dobaño; Denise Naniche; Alfredo Mayor; Jaume Ordi; Inacio Mandomando; John J Aponte; Samuel Mabunda; Pedro L Alonso
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more
  76 in total

1.  Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: the controversy continues.

Authors:  Julie Gutman
Journal:  Clin Infect Dis       Date:  2012-07-05       Impact factor: 9.079

2.  Defending the Use of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment for Malaria in Pregnancy: A Short-Sighted Strategy.

Authors:  Whitney E Harrington; Michal Fried; Patrick E Duffy
Journal:  J Infect Dis       Date:  2015-08-19       Impact factor: 5.226

3.  High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.

Authors:  Olusola Ojurongbe; Christian N Nguetse; Samuel A Fayemiwo; Catherine O Falade; Taiwo A Ojurongbe; Bolaji N Thomas; Christian G Meyer; Thirumalaisamy P Velavan
Journal:  Pathog Glob Health       Date:  2018-01-10       Impact factor: 2.894

Review 4.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

5.  Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.

Authors:  Steve M Taylor; Alejandro L Antonia; Ebbie Chaluluka; Victor Mwapasa; Gaoqian Feng; Malcolm E Molyneux; Feiko O ter Kuile; Steven R Meshnick; Stephen J Rogerson
Journal:  Clin Infect Dis       Date:  2012-03-22       Impact factor: 9.079

6.  A Malaria-Resistant Phenotype with Immunological Correlates in a Tanzanian Birth Cohort Exposed to Intense Malaria Transmission.

Authors:  Scott D Nash; D Rebecca Prevots; Edward Kabyemela; Yogender P Khasa; Kun-Lin Lee; Michal Fried; Patrick E Duffy
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

7.  Weighing for results: assessing the effect of IPTp.

Authors:  Julie Gutman; Erin Eckert; Viviana Mangiaterra; Azucena Bardají; John J Aponte; Clara Menéndez; Bernard Nahlen; Laurence Slutsker
Journal:  Lancet Infect Dis       Date:  2013-04       Impact factor: 25.071

8.  Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.

Authors:  Julie Gutman; Dyson Mwandama; Ryan E Wiegand; Doreen Ali; Don P Mathanga; Jacek Skarbinski
Journal:  J Infect Dis       Date:  2013-06-24       Impact factor: 5.226

9.  Reply to Harrington et al.

Authors:  Julie Gutman; Steve Taylor; Steven R Meshnick; Feiko O Ter Kuile
Journal:  J Infect Dis       Date:  2015-08-19       Impact factor: 5.226

10.  Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study.

Authors:  Rabi Ndeserua; Adinan Juma; Dominic Mosha; Jaffu Chilongola
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.